Investigational agents (unspecified)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Investigational agents (unspecified), covering 2026-03-31 to 2026-03-31. Get the full timeline:
Most recent: Clinical Trial Update: Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01) [Phase 2]